

(A)
% Cells undergoing EMT upon stimulation (based on morphology)
100
80
60
40
20
0
NS
TNF
EGF
IL6
TGF-
PMA
Stimuli
(B)
NS (Epithelial)
ST (Mesenchymal)
(C)
(i)
ST
0 hr
18 hr
Overlay
(ii)
NS
0 hr
18 hr
Overlay

FIGURE 1





FIGURE 1 Cont'd

(H)



(I)






FIGURE 1 cont'd


(A)



(B)



(C)



(D)




FIGURE 2





FIGURE 2 cont'd

(J)



(K)




FIGURE 2 cont'd



(A)
ST
(-) PKC-θ
peptide inhibitor
ST
(+) PKC-θ peptide
Inhibitor
30 nM
(B)
% CSC-like subpopulation
10
8
6
4
2
0
NS
ST
NS
ST
PKC-peptide inhibitor 30 nM
(-)
(-)
(+)
(+)
(C)
CD44 Arbitrary Copy Number (normalized to PPIA)
800
600
400
200
0
NS
ST
NS
ST
PKC-peptide inhibitor 30 nM
(-)
(-)
(+)
(+)
(D)
% CSC-like subpopulation
6
4
2
0
NS
ST
NS
ST
NS
ST
Mock siRNA
PKC-θ siRNA
PKC-β siRNA

FIGURE 3




FIGURE 3 cont'd



(A)
CD44 promoter
PKC- ChIP enrichment ratio
15
10
5
0
MCF-7 IM CSC
HMLE IM CSC
MDA MB-231
(B)
uPAR promoter
PKC-θ (phospho) ChIP enrichment ratio
1000
800
600
400
200
0
NS
ST
(C)
CD44 promoter
PKC-θ (phospho) ChIP enrichment ratio
600
400
200
0
NS
ST
(D)
uPAR promoter
Pol II enriched PKC-θ-P ChIP
80
60
40
20
0
NS
ST
(E)
uPAR promoter
PKC- ChIP enrichment ratio
20
15
10
5
0
(-)
(+)
(-)
(+)
BIS
PKC- siRNA

FIGURE 4



Normal
Invasive
Cytoplasmic PKC-θ
Normal
Invasive
Nuclear PKC-θ

FIGURE 5



A
PKC- activity (absorbance at 450nM)
C27 Inhibitor
B
% Inhibition of PKC- activity
C27 Inhibitor
Nuclei
Cytoplasm
C
% CSC subpopulation
C27 Inhibitor
D
CD44
PLAUR
Arbitrary copy number (normalized to PPIA)
C27 Inhibitor
E
Nuclear p50 activity (absorbance at 450nm)
Vehicle alone
C27 Inhibitor
F
Nuclear p65 activity (absorbance at 450nm)
Vehicle alone
C27 Inhibitor
G
C27 Inhibitor
ST NS ST NS
p65-P-468 (65 kDa)
Histone H3 (17 kDa)
p65-P-468
Relative abundance (Normalized to H3)
C27
H
C27 Inhibitor
(Nuclear Fraction)
ST NS ST NS
p65 (65 kDa)
Histone H3 (17 kDa)
Nuclear fraction p65
Relative abundance (Normalized to H3)
C27
I
C27 Inhibitor
(Cytoplasmic Fraction)
NS ST NS ST
p65 (65 kDa)
Tubulin (50 kDa)
Cytoplasmic fraction p65
Relative abundance (Normalized to H3)
C27
J
WCL
-AB +AB
PKC-θ
-AB IP PKCθ -IP
RNA Pol II (217 kDa)
P65 (65 kDa)
PKC-θ (82 kDa)

FIGURE 6